Stock Comparison

BEAM vs JNJ

Beam Therapeutics Inc vs Johnson & Johnson

The Verdict

BEAM takes this one.

Winner

BEAM

Beam Therapeutics Inc

9.1

out of 10

Hidden Gem

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$2.4B

Market Cap

N/A

0.0

P/E Ratio

N/A

-744.4%

Profit Margin

N/A

-47.2%

Return on Equity

N/A

0.2

Debt-to-Equity

N/A

Aggressive

Overall Risk

Conservative

9.1

DVR Score

1.0

The Deep Dive

BEAM9.1/10

Beam Therapeutics retains a high 10x growth potential, driven by its cutting-edge base editing platform, which continues to demonstrate significant promise for precision genetic cures. Recent positive developments, including the selection of an optimal dose for BEAM-302 in Phase 1/2 trials and the unveiling of the BEAM-304 PKU program (IND expected 2026), highlight strong execution and pipeline ex...

Full BEAM Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.